

Vutrisiran: Dosage and Administration

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for AMVUTTRA[®] (vutrisiran) is provided [here](#). Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.

INDEX

[Label Information](#) – [References](#)

AMVUTTRA PRESCRIBING INFORMATION – RELEVANT CONTENT

The DOSAGE AND ADMINISTRATION section provides the following information¹:

Recommended Dosage

The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months.

Missed Dose

If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose.

Administration Instructions

AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.

Preparation and Administration*

1. Prepare the syringe

- *If stored cold, allow the syringe to warm to room temperature for 30 minutes prior to use.*
- *Remove the syringe from the packaging by gripping the syringe body.*
 - **Do not** touch the plunger rod until ready to inject.
- *Visually inspect the drug solution for discoloration and particulate matter prior to administration. AMVUTTRA is a sterile, preservative-free, clear, colorless-to-yellow solution. **Do not** use if it contains particulate matter or if it is cloudy or discolored.*
- *Check the following:*
 - *Syringe is not damaged, such as cracked or leaking*
 - *Needle cap is attached to the syringe*
 - *Expiration date on syringe label*
- **Do not** use the syringe if any issues are found while checking the syringe.

2. Choose and prepare the injection site

- *Choose an injection site from the following areas: the abdomen, thighs, or upper arms.*
- *Avoid the following:*
 - *5-cm area around the navel*
 - *Scar tissue or areas that are reddened, inflamed, or swollen*

- *Clean the chosen injection site.*

3. Prepare the syringe for injection

- *Hold the syringe body with one hand. Pull the needle cap straight off with other hand and dispose of needle cap immediately. It is normal to see a drop of liquid at the tip of the needle.*
 - ***Do not*** touch the needle or let it touch any surface.
 - ***Do not*** recap the syringe.
 - ***Do not*** use the syringe if it is dropped.

4. Perform the injection

- *Pinch the cleaned skin.*
- *Fully insert the needle into the pinched skin at a 45°-90° angle.*
- *Inject all of the medication.*
 - ***Push the plunger rod as far as it will go*** to administer the dose and activate the needle shield.
- *Release the plunger rod to allow the needle shield to cover the needle.*
 - ***Do not*** block plunger rod movement.

5. Dispose of the syringe

- ***Immediately dispose*** of the used syringe into a sharps container.

*Please note: Illustrations are available in Section 2.2 of the Prescribing Information as part of the DOSAGE AND ADMINISTRATION section.

The DOSAGE FORMS AND STRENGTHS section provides the following information¹:

Injection: 25 mg/0.5 mL of vutrisiran as a clear, colorless-to-yellow solution in a single-dose prefilled syringe.

REFERENCES

1. AMVUTTRA (vutrisiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.

Updated 24 June 2024